Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Tumor derived MDA-MB-436 pLKO versus MDA-MB-436 shTONSL cells-enriched gene expression

ABSTRACT: Tumor derived MDA-MB-436 pLKO versus MDA-MB-436 shTONSL cells-enriched gene expression

PROVIDER: PRJNA892638 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21989270_1.fastq.gz	Fastqsanger.gz
	SRR21989270_2.fastq.gz	Fastqsanger.gz
	SRR21989271_1.fastq.gz	Fastqsanger.gz
	SRR21989271_2.fastq.gz	Fastqsanger.gz
	SRR21989272_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Tumor derived MDA-MB-436 pLKO versus MDA-MB-436 shTONSL cells-enriched gene expression

Project description:To study TONSL regulated genes in neoplastically transformed cells, we established tumor derived MDA-MB-436 cell lines in which TONSL is been knocked down by shRNA.

2023-10-31 | GSE216239 | GEO

Exon arrays from HT-29, MCF10A, and MDA-MB-436 cells

Project description:Expression data from HT-29 cells treated with IFN-γ for 24 hr, MCF10A cells, and MDA-MB-436 cells.

2013-08-06 | GSE45195 | GEO

RNA-seq analysis of HT-29, MCF10A, and MDA-MB-436 cells

Project description:RNA-seq data from HT-29 cells treated with IFN-M-NM-3 for 24 hr, MCF10A cells, and MDA-MB-436 cells. mRNA profiles of HT-29, MCF10A, and MDA-MB-436 were generated by deep sequencing using Illumina HiSeq 2000. All RNA sequencing data was generated by the Genomics Services Lab at the HudsonAlpha Institute for Biotechnology (Huntsville, AL).

2013-08-06 | E-GEOD-45258 | biostudies-arrayexpress

RNA-seq analysis of HT-29, MCF10A, and MDA-MB-436 cells

Project description:RNA-seq data from HT-29 cells treated with IFN-γ for 24 hr, MCF10A cells, and MDA-MB-436 cells.

2013-08-06 | GSE45258 | GEO

Exon arrays from HT-29, MCF10A, and MDA-MB-436 cells

Project description:Expression data from HT-29 cells treated with IFN-Î³ for 24 hr, MCF10A cells, and MDA-MB-436 cells. Total RNA was isolated with the RNeasy Mini Kit (Qiagen). Sense-strand cDNA synthesis, terminal labeling, and hybridization were performed using Ambion WT Expression Kit (Applied Biosystems, P/N 4425209).

2013-08-06 | E-GEOD-45195 | biostudies-arrayexpress

TWEAK-treated time course in MDA-MB-436 cells

Project description:Tumor necrosis factor-related weak inducer of apoptosis, TWEAK, is a TNF superfamily member that mediates signaling through its receptor fibroblast growth factor inducible-14, Fn14. In tumor cell lines, TWEAK induces proliferation, survival and NF-kappaB signaling and gene expression that promote tumor growth and suppress antitumor immune responses. Anti-TWEAK antibody, RG7212, inhibits tumor growth in vivo with decreases in pathway activation markers and modulation of tumor, blood and spleen immune cell composition. Candidate response prediction markers, including Fn14, have been identified in mouse models. Phase I pharmacodynamic data from patients are consistent with preclinical results. TWEAK:Fn14 signaling is upregulated in human cancer and pathway activation induces tumor proliferation and survival signaling. Blockade with anti-TWEAK mAb, RG7212, inhibits tumor growth in multiple models in mice. TWEAK induces changes that suppress anti-tumor immune responses and RG7212 blocks these effects resulting in changes in tumor immune cell composition and decreases in cytokines that promote immunosuppression. Antitumor efficacy in mice was observed in a range of Fn14 expressing models with pathway activation and expressing either wild-type or mutant p53, BRAF or KRAS suggesting both a patient selection strategy and potential broad clinical applicability. Preclinical mechanism of action hypotheses are supported by Phase I clinical data, with decreases in proliferation markers and increased tumor T cell infiltration. MDA-MB-436 cells untreated or treated with 1090-TW (TWEAK) for 15 minutes, 1 hour, 4 hours, 8 hours, or 24 hours. Five replicates for each condition were performed.

2013-10-04 | E-GEOD-42045 | biostudies-arrayexpress

Highly-motile versus unsorted MDA-MB-231 breast cancer cells

Project description:Highly-motile versus unsorted MDA-MB-231 breast cancer cells

| PRJNA527110 | ENA

Whole-genome decay rate measurements in MDA-MB-231 cells transfected with HNRPA2B1 siRNAs versus controls

Project description:Transcriptional profiling of MDA-MB-231 samples taken at 0, 1, 2 and 4hr timepoints upon exposure to alpha-amanitine, comparing the siRNA-mediated HNRPA2B1 knock-downs versus mock-transfected controls

2012-02-28 | GSE35756 | GEO

Transcriptomic analysis of DOXO-Resistant cells compared to parental DOXO-Sensitive mda-mb-436 cell line

Project description:The major obstacle in successfully treating triple negative breast cancer (TNBC) is resistance to cytotoxic chemotherapy, the mainstay of treatment in this disease. Previous pre-clinical models of chemoresistance in TNBC have suffered from a lack of clinical relevance. Using a single high dose chemotherapy treatment, we developed a novel MDA-MB-436 cell-based model of chemoresistance characterized by a unique and complex morphological phenotype, which consists of polyploid giant cancer cells (PGCCs) giving rise to neuron-like mononuclear daughter cells filled with smaller but functional mitochondria and numerous lipid droplets. This resistant phenotype is associated with metabolic reprogramming with a shift to a greater dependence on fatty acids and oxidative phosphorylation. We validated both the molecular and histologic features of this model in a clinical cohort of primary chemoresistant TNBCs and identified several metabolic vulnerabilities including a dependence on PLIN4, a perilipin coating the observed lipid droplets, expressed both in the TNBC resistant cells and clinical chemoresistant tumors treated with neoadjuvant doxorubicin-based chemotherapy. These findings thus reveal a novel mechanism of chemotherapy resistance that has therapeutic implications in the treatment of drug resistant cancer.

2019-11-30 | GSE138233 | GEO

siRNA-mediated HNRPA2B1 knock-down in MDA-MB-231 cells

Project description:Transcriptional profiling of MDA-MB-231 comparing the siRNA-mediated HNRPA2B1 knock-downs versus mock-transfected controls

2012-02-28 | GSE35757 | GEO